Table 4.
Postmortem studies of the CB1 receptors in psychotic disorders.
| Condition & brain region | n (cases/controls) | Autoradiography | 1Antibody | mRNA | Reference |
|---|---|---|---|---|---|
| Dorsolateral prefrontal cortex | |||||
| Schizophrenia | 20/20 | - | Uriguen et al., 2009 | ||
| (untreated) | 5/5 | n.s. IB | n.s. qPCR | ||
| (treated) | 11/11 | ↓IB | n.s. qPCR | ||
| Schizophrenia | 37/37 | - | Dalton et al., 2011 | ||
| (paranoid) | 16/37 | ↑[3H]CP55,940 | n.s. qPCR | ||
| (non-paranoid) | 21/37 | n.s. [3H]CP55,940 | n.s. qPCR | ||
| Schizophrenia | 14/14 | ↑[3H]CP55,940 | - | - | Dean et al., 2001 |
| Schizophrenia | 47/43 | ↑[3H]MePPEP | - | - | Jenko et al., 2012 |
| Schizophrenia2 | 12/12 | ↑[3H]OMAR | ↓CB1 | ↓CB1 ISH | Eggan et al., 2008; |
| 21/21 | Volk, D. W. et al., 2014 | ||||
| Schizophrenia3 | 14/14 | - | ↓CB1 | - | Eggan et al., 2010 |
| Anterior cingulate cortex | |||||
| Schizophrenia | 10/9 | ↑[3H]SR141716A | - | - | Zavitsanou et al., 2004 |
| Schizophrenia | 15/15 | - | n.s. CB1 (neurons and glia) | - | Koethe et al., 2007 |
| Posterior cingulate cortex | |||||
| Schizophrenia | 8/8 | ↑[3H]CP55,940 | - | - | Newell et al., 2006 |
| Medial temporal lobe | |||||
| Schizophrenia | 14/14 | n.s. [3H]CP55,940 | - | - | Dean et al., 2001 |
| Superior temporal gyrus | |||||
| Schizophrenia | 8/8 | n.s. [3H]CP55,940 n.s.[3H]SR141716A |
- | - | Deng et al., 2007 |
| Striatum | |||||
| Schizophrenia | 14/14 | n.s. [3H]CP55,940 | - | - | Dean et al., 2001 |
↑: higher; ↓: lower; n.s.: no significant difference from controls; -: no available data;
CB1 agonist: [3H]CP55,940; CB1 antagonist: [3H]MePPEP, [3H]OMAR, [3H]SR141716A;
IB: Immunoblotting; ICC: immunocytochemistry; IHC: immunohistochemistry; qPCR: Quantitative real-time polymerase chain reaction; ISH: in situ hybridization;
1
Measured using immunocytochemistry unless noted as immunoblot IB.
2
Eggan et al. 2008 and Volk et al., 2014 tested tissue from the same patients.
3
This sample consists of a subset from Eggan et al, 2008 study.